MAPT and myotonic dystrophy type 1: The goal of this exploratory study was thus to investigate Tau pathology in vivo in a small but well-characterized sample of DM1 participants using several biomarkers of neurodegeneration, including [18F]-AV-1451 Tau PET imaging, CSF and plasma biomarkers.